Complications of Diabetes: Prevention, Early Screening, and Trajectory Guide

---

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

---

In Brief: Your Routine Screening Schedule for Type 2 Diabetes

The systemic complications of diabetes develop silently. They build through a long asymptomatic phase — and that phase is when intervention works best. Retinopathy starts as microaneurysms visible only on a dilated exam, kidney disease as albumin leaking into urine, neuropathy as subtle loss of monofilament sensation. By the time vision changes, swelling, or foot wounds appear, options have narrowed. Comprehensive intervention — blood pressure, lipids, glucose, smoking cessation, and the modern organ-protective medications — produces better outcomes than any single piece alone, and many people with diabetes never develop severe complications when risk factors are addressed early. This article covers what to screen for, what the numbers mean, when to act on warning signs, and how the system fits together.

Blood vessels experience the metabolic environment continuously, even when symptoms are absent.

---

Before You Feel Anything: Spotting Early Warning Signs of Diabetic Retinopathy

The Early Warning Signs of Diabetic Retinopathy are completely asymptomatic; the disease does not start the day you notice blurry lines, but years earlier as microaneurysms — tiny bulges in retinal capillaries visible only on a dilated eye exam. You feel nothing. Your vision is fine. The damage is accumulating. The same pattern holds for kidney disease (albumin leaking into urine years before symptoms) and neuropathy (loss of sensation on a monofilament long before any wound). Every major diabetes complication has a long preclinical phase where screening can detect it, followed by a symptomatic phase where options narrow.

But complications are not destiny. Rates of blindness, dialysis, and amputation from diabetes have declined substantially over recent decades — because of earlier detection, better blood pressure control, statins, retinal treatment, and newer kidney-protective therapies. The biology develops in detail in Article 3; the practical point is that screening works in diabetes because progression is usually slow enough that routine testing detects disease years before irreversible damage.

In the Steno-2 trial, people with Type 2 diabetes who addressed all major risk factors together — blood pressure, cholesterol, glucose, smoking — gained a median of 7.9 years of survival compared with standard care.³ Not months. Nearly eight years. The intervention was not a breakthrough drug. It was systematic risk-factor management plus screening for what cannot be felt.

Complication prevention is cumulative. Each piece — blood pressure, lipids, glucose, smoking cessation, screening — adds to the others rather than acting alone.

---

Why the Complications of Diabetes Screening Framework Is Manageable

Managing diabetes already requires constant attention. Adding complication screening can feel like one more demand. What keeps it workable is that most screenings are annual, quick, and high-yield — the calendar exists so complications do not have to occupy daily thought. Show up, get the tests, learn where things stand, and move on.

A well-managed diabetes trajectory is real and common: no retinopathy on annual exams (or mild changes that stabilized), eGFR in the normal range with no albumin in urine, feet with intact sensation, and cardiovascular risk managed with the same tools anyone uses. Many people stay on this trajectory for decades. And when complications do develop — which is also common — slowing progression meaningfully changes long-term function, quality of life, and survival. Partial success matters. Late intervention still works.

---

Type 1 vs Type 2: Natural Differences in the Complications of Diabetes

Most of the screening cadences and trial evidence in this article come from Type 2 diabetes, but the underlying complications are similar in both. Two practical differences are worth establishing up front, because they shape how the rest of the article applies.

The progression of diabetes complications differs fundamentally between Type 1 and Type 2:

• Type 1 complications typically take 10 to 20 years to develop, whereas Type 2 complications can be present right at the time of diagnosis.
• Screening begins 5 years after diagnosis for Type 1, but starts immediately at diagnosis for Type 2.
• Cardiovascular risk is generally lower in Type 1 but spikes severely if kidney disease develops.
• SGLT2 inhibitors are not indicated for Type 1 in the U.S. due to DKA risks and require strict specialist oversight if used off-label.

---

Following a Structured Routine Screening Schedule for Type 2 Diabetes

Maintaining a Routine screening schedule for type 2 diabetes ensures that each item in the screening calendar catches a different injury before symptoms appear.

Screening	When to start	How often	Why it matters
Dilated eye exam	Type 2: at diagnosis; Type 1: 5 years after	Annually (may extend to every 2 years if no retinopathy and well-controlled)	Detects retinal injury before vision loss; over 90% of severe vision loss is preventable when caught¹⁰
Kidney function (eGFR + urine ACR)	At diagnosis	Annually (more often if abnormal)	Detects kidney injury years before symptoms; also a marker of systemic vascular risk¹⁰,¹²
Comprehensive foot exam	At diagnosis	Annually (more often with neuropathy or prior ulcer)	Identifies loss of protective sensation before ulcers develop¹⁶
Blood pressure	At diagnosis	At every visit; home monitoring encouraged	One of the strongest drivers of complication progression¹¹
Lipid panel	At diagnosis	Annually (may extend if stable and at goal)	Identifies modifiable atherosclerotic risk¹⁰
A1C	At diagnosis	Every 3 months if not at goal; every 6 months if stable	Tracks cumulative glucose exposure and treatment response
Vaccinations	At diagnosis, then per age-based schedule	Annual (flu), per schedule for others	People with diabetes are at higher risk of severe outcomes from infections¹⁰
Dental visit	At diagnosis	Twice yearly	Periodontal disease is bidirectionally linked to diabetes¹⁰

Pregnancy changes things. Women with preexisting diabetes need retinal exams each trimester — retinopathy can progress rapidly during pregnancy — and preconception counseling helps optimize A1C before the stakes are highest.¹⁰

Staying up to date on immunizations is a critical component of preventative care:

• Necessary routine vaccines include annual flu, pneumococcal, hepatitis B, shingles, COVID-19 boosters, RSV, and Tdap.
• People with diabetes face a much higher risk of severe illness and complications from common infections.
• Severe infections can cause dangerous spikes in blood sugar, triggering emergency conditions like diabetic ketoacidosis or hyperosmolar crises.

---

What Each Diagnostic Test and Biomarker Actually Means

Numbers without context are just data. What each cutoff actually represents matters more than the number itself.

Evaluating Estimated GFR and Kidney Function Metrics

Kidneys are tracked with two complementary tests: eGFR (how well they filter) and ACR (whether they are leaking protein).

eGFR (Estimated GFR and kidney function):

eGFR (mL/min/1.73 m²)	What it means
≥90	Normal
60–89	Mildly decreased (common with age; not necessarily CKD alone)
45–59	Moderately decreased
30–44	Significantly decreased
15–29	Severely decreased
<15	Kidney failure

ACR (Urine albumin to creatinine ratio):

ACR (mg/g)	What it means
<30	Normal
30–300	Moderately increased albuminuria (often improvable with treatment)
>300	Severely increased albuminuria

These two numbers tell different parts of one story. Someone with eGFR 55 and ACR 25 is in a different situation than someone with eGFR 55 and ACR 400. The combination determines risk and treatment urgency.¹⁰,¹² CKD staging requires abnormalities persisting at least three months; one abnormal result triggers repeat testing, not conclusions.

Why albuminuria matters beyond the kidney. Albuminuria is not just a kidney number. It is one of the strongest predictors of cardiovascular events and mortality in diabetes — because it reflects systemic vascular injury that is occurring simultaneously in the kidneys, heart, brain, and peripheral vessels. Treating albuminuria treats more than the kidney.

Retinopathy Staging and Preventive Vision Tracking

Stage	What’s happening	What you notice	What happens next
No retinopathy	Normal exam	Nothing	Annual screening
Mild NPDR	Microaneurysms only	Nothing	Annual screening; may regress with good control
Moderate NPDR	Hemorrhages, cotton-wool spots, hard exudates	Usually nothing	Closer follow-up; possibly retina referral
Severe NPDR	Extensive damage, high progression risk	Usually nothing	Retina specialist; treatment often considered
Proliferative (PDR)	Abnormal new blood vessels growing	Floaters, vision loss	Urgent treatment: laser, anti-VEGF injections, possibly surgery
Macular edema (DME)	Fluid in the central retina	Central blur, distortion	Can occur at any stage; anti-VEGF injections are first-line

About half of eyes with severe NPDR progress to proliferative disease within a year without treatment. With treatment, over 90% of severe vision loss is preventable.¹⁰

Assessing Lower Extremity Foot Risk Categories

Category	What it means	Exam frequency
0	Normal sensation, normal circulation	Yearly
1	Loss of protective sensation	Every 6–12 months
2	Neuropathy plus poor circulation or deformity	Every 3–6 months
3	Prior foot ulcer or amputation	Every 1–3 months

Loss of protective sensation means inability to feel the 10-gram monofilament a clinician presses against the foot — the threshold below which small injuries can go unnoticed.¹⁶ Neuropathy alone does not cause ulcers. Ulcers usually develop when neuropathy combines with pressure (poorly-fitting shoes, abnormal gait), deformity (bunions, hammer toes, Charcot changes), or impaired circulation.

---

Clinical Target Guidelines to Limit the Complications of Diabetes

These are common guideline frameworks for clinician decision-making, not personal prescriptions. Individual goals depend on age, comorbidities, hypoglycemia risk, frailty, life expectancy, and patient preference.¹⁰

A1C. Most adults: <7%. Younger, newly diagnosed, no cardiovascular disease: <6.5% if achievable without significant hypoglycemia. Older adults, multiple comorbidities, or high hypoglycemia risk: <8% or individualized.

Blood pressure. Most adults with diabetes: <130/80 mmHg. The evidence base here is nuanced — UKPDS established that lowering blood pressure substantially reduces complications, but its “tight” comparison (144/82 vs 154/87) is above modern targets.¹¹ ACCORD-BP, which compared <120 vs <140 systolic in Type 2 diabetes, did not show benefit on the primary composite but did show reduced stroke. Most current guidelines favor <130/80 based on the combined data.¹⁰ Higher targets (around 140/90) may be appropriate when fall risk or orthostatic hypotension is significant. Resistant hypertension — uncontrolled despite three medications including a diuretic — warrants workup for renal artery stenosis, primary aldosteronism, sleep apnea, and medication non-adherence.

LDL cholesterol. Established cardiovascular disease: <70 mg/dL (some guidelines say <55). No cardiovascular disease, age 40–75: <100 mg/dL or at least 50% reduction with statin. Over 75: individualized.

---

Why Early Screening Works: Understanding Metabolic Memory Diabetes

The biology behind every recommendation in this article is developed in detail in Article 3. The short version: chronic high glucose damages blood vessels through several interconnected pathways operating simultaneously.

Glucose first reversibly attaches to proteins, then over months to years forms advanced glycation end products (AGEs)— the end products of a slow Maillard reaction between sugars and long-lived structural proteins. AGEs accumulate in arterial walls, capillary basement membranes, collagen, and crystallin (the lens protein). This is chemistry that does not reverse on its own; once formed, AGEs persist.

Their accumulation is the molecular basis for Metabolic memory diabetes — the observation, established in the DCCT/EDIC long-term follow-up, that sustained good control leaves a lasting biologic effect, and sustained poor control leaves lasting damage that persists even after control improves. The former intensive-control arm had a 57% reduction in major cardiovascular events 10+ years later, even after A1C had converged between groups.²,⁴ Early action matters because what accumulates does not easily reverse.

In nerves and the lens, excess glucose is also converted to sorbitol, which accumulates and damages cells — contributing to the burning pain of neuropathy and the clouding of cataracts.⁷ Throughout the body, excess glucose overwhelms cellular metabolism, generating oxidative stress that injures vessel linings; the body responds with chronic low-grade inflammation that accelerates atherosclerosis.⁵,⁶

These processes affect small vessels (retina, kidney glomeruli, nerve capillaries) and large vessels (coronary, cerebral, peripheral arteries) simultaneously. That is why someone with retinopathy is also at elevated risk for heart attack — the damage is systemic. Retinopathy and albuminuria are not isolated complications. They are markers that the underlying vascular disease process is active throughout the body.

Why blood pressure matters as much as glucose. Hypertension amplifies every mechanism above. It increases shear stress on already-damaged vessels, accelerates atherosclerosis, and worsens the pressure load on kidney filtering units. The combination of high glucose and high blood pressure is synergistically worse than either alone — which is why blood pressure control often produces effect sizes as large as glucose control in trials.¹¹

Diabetes complications progress slowly enough that routine screening can detect disease years before irreversible damage occurs.

---

Eyes: Clinical Guidelines for Intensive Diabetic Retinopathy Screening

Roughly 28% of U.S. adults with diabetes had some retinopathy and about 4% had vision-threatening disease in 2005–2008 surveillance data;⁸ more recent estimates suggest higher prevalence as the diabetes population ages. With proactive Diabetic retinopathy screening and timely treatment, over 90% of severe vision loss is preventable.¹⁰

Why the retina is uniquely vulnerable. The retina has very high metabolic demand per unit mass, depends on an extraordinarily dense capillary network, and lacks collateral circulation — so when small vessels close, the affected tissue has no alternative blood supply. Chronic glucose injury hits the retina earlier and harder than most tissues.

Retinal damage follows a predictable multi-stage degenerative pathway over time:

• Chronic high blood sugar breaks down retinal capillary walls and destroys their structural support cells.
• Weakened vessels form microaneurysms that leak fluid or close entirely, cutting off oxygen to the eye tissue.
• Oxygen-starved tissue releases growth factors that force the creation of abnormal, highly fragile new blood vessels.
• These new vessels rupture and bleed easily, leading to vitreous hemorrhage, progressive tissue scarring, and retinal detachment.

Progression risk increases with severity. Mild and moderate NPDR have relatively low short-term progression risk. Severe NPDR has high risk of progressing to proliferative disease within one to two years. Untreated PDR carries substantial risk of severe vision loss within five years.⁹

Treatment. For NPDR, the primary treatment is optimizing glucose and blood pressure; mild and even moderate NPDR can stabilize or regress with good control. For severe NPDR and PDR, options include panretinal photocoagulation (laser) and anti-VEGF injections (bevacizumab, ranibizumab, aflibercept, and the newer agent faricimab); anti-VEGF is increasingly first-line for PDR. Vitrectomy may be needed if vitreous hemorrhage obscures the view or tractional detachment threatens the macula. For diabetic macular edema, anti-VEGF injections are first-line for center-involving disease, typically using treat-and-extend protocols rather than fixed monthly schedules; focal laser is still used for non-center-involving DME.⁹

---

Kidneys: Key Strategies for Preventing Diabetic Kidney Disease

About 40% of people with diabetes develop chronic kidney disease. Focusing on Preventing Diabetic Kidney Disease is a clinical priority, as it remains the leading cause of end-stage kidney disease requiring dialysis.¹²

Kidney failure develops sequentially as structural filtering units break down under pressure:

• Early kidney damage begins when the filtering units overwork and experience structural strain from hyperfiltration.
• Vital filtering cells called podocytes are steadily injured and permanently lost over time.
• The filtering membrane thickens abnormally, which allows blood proteins like albumin to leak out into the urine.
• As filtering units continue to burn out and die off, overall kidney function scores safely decline.

Without intervention, roughly 20–40% of people with moderately increased albuminuria progress to severely increased albuminuria over ten years. Historically, median time from severe albuminuria to kidney failure was seven to ten years. With modern nephroprotection, progression is substantially slower.

The Four Pillars: Optimizing SGLT2 Inhibitors and Kidney Protection

Modern diabetic kidney disease care rests on four medication categories used together, alongside blood pressure control and the lifestyle foundation in Article 6.

1. ACE inhibitors or ARBs. Reduce pressure inside the glomerulus, decrease albuminuria, and slow progression. Recommended for people with diabetes and albuminuria (ACR ≥30), and for blood pressure control in diabetes more broadly when an antihypertensive is indicated.¹⁰ A modest rise in creatinine after starting or increasing the dose is expected and generally acceptable; labs are typically rechecked within a few weeks. A large or sustained rise may indicate renal artery stenosis or volume depletion. ACE inhibitor and ARB are not combined; trials showed more harm and no benefit.¹⁰

2. SGLT2 inhibitors. The therapeutic link between SGLT2 inhibitors and kidney protection is well-established; in CREDENCE, canagliflozin reduced the primary kidney composite (end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death) by 30% in T2D with diabetic kidney disease.¹³ In DAPA-CKD, dapagliflozin reduced the primary composite (≥50% eGFR decline, end-stage kidney disease, or renal or cardiovascular death) by 39% — and the benefit extended to CKD patients without diabetes.¹⁴ Current labels support initiation in T2D with kidney disease at eGFR as low as 25 (dapagliflozin) and 20 (empagliflozin), with continuation typically appropriate as eGFR declines further until dialysis or transplant.¹⁰ An initial small dip in eGFR after starting reflects the drug’s hemodynamic effect, not kidney damage, and typically stabilizes. Side effects and cautions are covered in Article 7.

3. Finerenone. A non-steroidal mineralocorticoid receptor antagonist that reduces inflammation and fibrosis in kidneys and the cardiovascular system. In FIDELIO-DKD, finerenone reduced the kidney composite outcome by 18% in T2D with CKD on background ACEi or ARB.¹⁸ FIGARO-DKD showed a 13% reduction in the cardiovascular composite in a broader CKD population.²² For patients with continued albuminuria despite SGLT2 inhibitor and ACE inhibitor or ARB therapy, finerenone provides additional protection. Hyperkalemia is the main caution; potassium and kidney function are monitored at initiation and periodically.

4. GLP-1 receptor agonists for CKD. The FLOW trial (2024) demonstrated that semaglutide reduced major kidney disease events (≥50% sustained eGFR decline, kidney failure, kidney death, or cardiovascular death) by 24% in T2D with CKD, with a confirmatory secondary endpoint of major adverse cardiovascular events reduced by 18% and all-cause mortality reduced by 20%.²¹ The trial was stopped early for efficacy. The FDA approved semaglutide for this indication in January 2025, formally establishing GLP-1 receptor agonists as a fourth pillar of nephroprotection — particularly relevant when weight reduction or atherosclerotic cardiovascular disease is also present.

Blood pressure control sits alongside all four pillars; target is generally <130/80, achieved with the medications above plus additional agents as needed (typically a dihydropyridine calcium channel blocker or thiazide-like diuretic).

Other Medication and Dosing Choices for Diabetic Nephropathy ICD 10 Management

Metformin — caution at eGFR 30–45 (often with dose reduction); generally discontinued below 30. Held during acute illness or before procedures with intravenous contrast to reduce the rare but serious risk of lactic acidosis.¹⁰

NSAIDs — avoided when managing diabetic nephropathy icd 10 conditions; they accelerate progression and can cause acute kidney injury.

Dose adjustments — many medications need dose reduction as eGFR declines. Reviewing the full medication list with a pharmacist or clinician when kidney function changes is standard.

When to See a Nephrologist

Consider referral when eGFR drops below 30; when eGFR is declining more than ~5 mL/min/year; when potassium repeatedly limits the use of evidence-based medications; when the diagnosis is uncertain; or when planning for dialysis or transplant — ideally at eGFR 15–20, before crisis.¹⁰

---

When to Seek a Nephrologist Referral for Diabetic Nephropathy

Up to 50% of people with diabetes develop neuropathy over their lifetime.¹⁵ The most common form is distal symmetric polyneuropathy — the “stocking-glove” pattern affecting feet first, then hands.

Symptoms. Classic diabetic peripheral neuropathy symptoms include numbness, tingling, burning, or “pins and needles” — often worse at night. Some people describe walking on cotton, or not being able to feel where their feet are. As it progresses, sensation decreases and eventually disappears. Evaluating the symptoms of diabetic neuropathy foot pain reveals that painful neuropathy and numb neuropathy can coexist — burning in some areas, complete numbness in others. Paradoxically, painful neuropathy sometimes feels better as nerves become more damaged; that is loss of function, not improvement.

Screening. Annual exam testing protective sensation with a 10-gram monofilament and vibration sense with a 128-Hz tuning fork. Inability to feel the monofilament at one or more standard sites indicates loss of protective sensation — meaning wounds may go unnoticed.

Treatment. No medication regenerates damaged nerves. The focus is preventing progression (glucose, blood pressure, smoking cessation) and managing symptoms. For painful neuropathy, first-line options include duloxetine, pregabalin, or gabapentin, started at low doses and titrated based on response and tolerability.¹⁵ Second-line options — tricyclic antidepressants (amitriptyline, nortriptyline, used cautiously in older adults), topical capsaicin, and lidocaine patches — are often added in combination. Long-term opioids are generally avoided.

Fall risk. Loss of sensation impairs balance and position awareness, increasing fall risk — especially in older adults. A neuropathy assessment includes gait, footwear, home safety, and fall prevention, not just pain management.

Nerves: Identifying Common Diabetic Peripheral Neuropathy Symptoms

Autonomic Neuropathy: Exploring the Connection Between Diabetes and Silent Heart Attacks

Diabetes can also damage the nerves controlling automatic functions.

• Heart — resting tachycardia, orthostatic hypotension (dizziness on standing), exercise intolerance, and asymptomatic cardiac ischemia, which underscores The connection between diabetes and silent heart attacks.
• Gut — gastroparesis (delayed stomach emptying causing nausea, early satiety, and glucose absorption that is out of sync with insulin action, producing both highs and lows after meals), constipation, or diarrhea.
• Bladder — incomplete emptying, overflow incontinence, recurrent urinary tract infections.
• Sexual function — erectile dysfunction, vaginal dryness.

Erectile dysfunction deserves direct attention — not just because it affects quality of life, but because in men with diabetes it is often the first vascular symptom to appear, predicting future coronary events by several years. ED in a man with diabetes warrants cardiovascular risk assessment, not just symptomatic treatment.

Not Everything Is Diabetic Neuropathy: Differential Clinical Testing

Before assuming neuropathy is from diabetes, other causes are considered: B12 deficiency (especially common with long-term metformin use — checking B12 is standard if neuropathy develops), hypothyroidism, alcohol-related neuropathy, and rarely monoclonal gammopathy or other conditions. A basic workup includes B12, TSH, and additional testing if the pattern is atypical (asymmetric, rapidly progressive, predominantly motor).

---

Feet: Clinical Strategies for Preventing Diabetic Foot Ulcers and Amputations

Approximately 85% of diabetes-related amputations are preceded by a foot ulcer.¹⁶ Consequently, preventing diabetic foot ulcers is paramount to long-term limb preservation. Ulcers do not appear from nowhere — they result from neuropathy (the injury cannot be felt), poor circulation (the wound cannot heal), and pressure or deformity (an abnormal pressure point creates the injury in the first place).

The Diabetic Foot Exam: Circulation, Pulses, and Sensation Checks

A complete annual foot exam includes:

Visual inspection — dry skin, cracks, calluses, blisters, fungal nails, deformities (bunions, hammer toes, Charcot changes), and any wounds.

Vascular assessment — palpating dorsalis pedis and posterior tibial pulses. If pulses are weak or absent, ankle-brachial index (ABI) testing helps quantify circulation. ABI <0.9 indicates peripheral artery disease. In diabetes, however, ABI can be falsely normal or elevated (>1.4) because of calcified, non-compressible vessels — so toe-brachial index or vascular imaging is preferred when ABI is unreliable or symptoms suggest PAD despite a normal value.

Sensory testing — the 10-gram monofilament pressed against the sole (typically great toe and metatarsal heads), and a 128-Hz tuning fork over the great toe for vibration sense.

Daily Home Care: Managing Symptoms of Diabetic Neuropathy Foot Pain

• Inspect feet every day, including between toes; use a mirror or ask someone for help with the soles.
• Wash daily with lukewarm water (test temperature with the elbow or a thermometer — scalding water may not be felt). Do not soak — it macerates skin.
• Dry thoroughly, especially between toes.
• Moisturize tops and soles, but not between toes.
• Trim nails straight across, not into corners; thick nails or poor vision are reasons to see a podiatrist.
• Never go barefoot, even indoors. Check inside shoes before putting them on.
• Break in new shoes gradually.

When Acute Foot Issues Arise: Recognizing Warning Signs of Charcot Foot

Any wound in a neuropathic foot is treated as urgent — contact a clinician or urgent care promptly; do not “wait and see.” Signs of infection (redness, warmth, swelling, drainage, red streaks, fever) need urgent attention; foot infections in diabetes can progress to bone involvement (osteomyelitis) quickly.

Acute Charcot foot. Identifying the primary warning signs of charcot foot is critical, as it presents as a red, hot, swollen foot, often without an obvious wound. It is frequently mistaken for cellulitis or gout. The clue is that pain is often less than the appearance would predict, because of neuropathy. While clinical teams frequently evaluate whether can diabetic foot charcot be reversed, continued weight-bearing on an untreated Charcot foot can rapidly worsen deformity and lead to bone collapse — imaging (X-ray, often MRI) is typically needed to distinguish from osteomyelitis and to guide immobilization. Unexplained foot swelling and warmth in someone with neuropathy warrants urgent evaluation, with immobilization until the diagnosis is established.

---

Managing Diabetes with Peripheral Arterial Disease ICD 10 Coding and Risk Factors

Circulation issues in the legs present unique clinical challenges for diabetic patients:

• Peripheral artery disease occurs significantly more often in people with diabetes than in the general public.
• The arterial blockages selectively target smaller vessels lower down in the legs, below the knee.
• The disease is highly widespread and frequently calcified, making surgical interventions and accurate testing much harder.

Symptoms include intermittent claudication (calf pain with walking that resolves with rest), rest pain in the foot (often worse lying down, better with the leg dangling), non-healing wounds, or in advanced disease, tissue loss. Many people with diabetes have PAD without typical claudication because neuropathy masks the pain; this is one reason routine pulse checks and ABI testing matter.

For individuals diagnosed with diabetes with peripheral arterial disease icd 10 parameters, management is multimodal: smoking cessation (the single highest-yield intervention), supervised exercise therapy (which improves walking distance), statin therapy, antiplatelet therapy (usually aspirin or clopidogrel), and tight blood pressure and glucose control. Revascularization — endovascular or surgical — is considered for severe symptoms, limb-threatening ischemia, or non-healing wounds. Critical limb-threatening ischemia (rest pain, tissue loss, or gangrene) is a vascular surgery emergency.

---

Heart: Understanding Your Total Cardiovascular Disease Diabetes Risk Profile

Mitigating Cardiovascular disease diabetes risk is critical, as cardiovascular disease is the leading cause of death in people with diabetes — responsible for more mortality than blindness, kidney failure, and amputations combined.1,10 The same vascular damage affecting eyes, kidneys, and feet is occurring in coronary arteries simultaneously.

Plaque accumulation in the coronary arteries behaves more aggressively in diabetic patients:

• Plaque buildup in diabetes typically involves multiple coronary arteries over long, continuous stretches rather than a single spot.
• Because the blockages are so widespread, open-heart bypass surgery consistently outperforms standard stenting procedures.
• This extensive level of vessel damage demands highly aggressive, multi-pronged risk management.

Atypical presentations are common. People with diabetes, especially with autonomic neuropathy, are more likely to have asymptomatic cardiac ischemia. Heart attacks may present with shortness of breath, fatigue, nausea, or sweating rather than classic chest pain. The threshold for cardiac evaluation should be lower than for a non-diabetic patient.¹⁷

Smoking and diabetes are not additive — they are synergistic. Smoking amplifies every pathway through which diabetes damages vessels: endothelial dysfunction, oxidative stress, inflammation, prothrombotic shifts. Combined, they dramatically accelerate peripheral artery disease, heart attack risk, and wound-healing failure. Smoking cessation is the single highest-yield cardiovascular intervention available in diabetes — covered in Article 6.

Risk Reduction: Blood Pressure, High-Intensity Statins, and Antiplatelet Rules

Blood pressure control — target <130/80 for most adults with diabetes. First-line agents are ACE inhibitors or ARBs (which also protect kidneys), calcium channel blockers, and thiazide-like diuretics. Most people need two to three medications to reach target; starting with combination therapy is reasonable when BP is well above goal at diagnosis.¹⁰

Statin therapy — for most adults with diabetes aged 40–75, regardless of baseline LDL. High-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) for those with established cardiovascular disease or very high risk; moderate intensity for others. If LDL is not at goal on maximum tolerated statin, ezetimibe is added. For patients with established cardiovascular disease who remain above target on statin plus ezetimibe, PCSK9 inhibitors (evolocumab, alirocumab) or the twice-yearly siRNA inclisiran provide substantial additional LDL reduction with proven event reduction. Bempedoic acid is an option for statin-intolerant patients and reduced major cardiovascular events in CLEAR Outcomes — a particularly relevant trial because two-thirds of participants had diabetes.²⁵

Statin discontinuation due to perceived side effects is a major source of preventable cardiovascular events. The SAMSON trial used a blinded crossover design with statin, placebo, and no-tablet months and found that 90% of the symptom burden patients attributed to statins was also elicited by identical-looking placebo — implicating the nocebo effect more than the drug.²³ Half of SAMSON participants successfully resumed statin therapy after seeing their own data. Discussing concerns with the care team before stopping is worth the conversation; switching agents or doses, or temporary holds with re-challenge, often resolves perceived intolerance.

SGLT2 inhibitors and GLP-1 receptor agonists — beyond glucose lowering, multiple agents have proven cardiovascular benefit, covered in Article 7. SGLT2 inhibitors are guideline-recommended for diabetes plus heart failure or chronic kidney disease, regardless of A1C. GLP-1 receptor agonists are preferred when atherosclerotic disease is dominant or weight reduction is a goal. Combining both classes is increasingly common in high-risk patients with both atherosclerotic disease and heart-kidney involvement, and trial data support additive benefit.

Aspirin. Standard in secondary prevention (established cardiovascular disease). For primary prevention the picture has shifted: ASCEND showed a modest event reduction in diabetes offset by increased major bleeding,²⁴ and ASPREE and ARRIVE deflated enthusiasm in non-diabetic populations. The USPSTF recommends against initiating aspirin in adults 60 and older for primary prevention and favors individualized decisions for ages 40–59 at elevated cardiovascular risk. Current ADA guidance limits primary-prevention aspirin to high cardiovascular risk with low bleeding risk, with periodic reassessment.¹⁰

Lifestyle. 150 minutes per week of moderate-intensity aerobic activity; resistance training two to three times per week; smoking cessation; Mediterranean or DASH-style dietary pattern; weight management. Article 6 develops the evidence base.

Heart Failure: Protecting Against Cardiomyopathy with SGLT2 Inhibitors

Diabetes increases heart failure risk independent of coronary disease. Both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) are more common in diabetes.

A recognized entity called diabetic cardiomyopathy describes heart muscle injury from chronic glucose exposure, AGE accumulation, microvascular disease, and autonomic dysfunction — occurring even without significant coronary disease or hypertension. It produces diastolic dysfunction first, then can progress to either HFrEF or HFpEF.

HFpEF is the more recent treatment story. For decades, HFpEF — which represents roughly half of all heart failure — had no therapies proven to reduce hospitalizations or mortality. That changed with EMPEROR-Preserved (2021) and DELIVER (2022), which showed that SGLT2 inhibitors meaningfully reduce heart failure hospitalization in HFpEF regardless of diabetes status.²⁰ For people with both diabetes and HFpEF, this represents the first major treatment advance in a previously refractory condition. SGLT2 inhibitors also benefit HFrEF (DAPA-HF, EMPEROR-Reduced), making them broadly indicated across the heart failure spectrum. If diabetes and heart failure coexist, an SGLT2 inhibitor is recommended unless specifically contraindicated. Detailed heart failure pharmacology — including foundational therapy for HFrEF — is developed in Article 7.

Slowing Stroke Risk and Managing Atrial Fibrillation in Diabetes

Stroke risk in diabetes is roughly doubled compared with non-diabetic populations. Prevention rests on the same pillars as coronary risk reduction: blood pressure control (particularly important — UKPDS showed BP control reduced stroke by 44%¹¹), statin therapy, glucose management, and smoking cessation.

Atrial fibrillation is more common in diabetes and is a major contributor to stroke. Pulse irregularity at clinic visits or palpitations warrants evaluation with an ECG and sometimes ambulatory monitoring. When atrial fibrillation is diagnosed, anticoagulation decisions are based on the CHA₂DS₂-VASc score; diabetes contributes one point, increasing the likelihood that anticoagulation is recommended.

---

Other Clinical Systems Vulnerable to the Complications of Diabetes

Diabetes affects more than eyes, kidneys, nerves, and heart. Three additional areas are common, modifiable, and often missed.

Liver Health: Tracking Non-Invasive Fibrosis Scores in MASLD and MASH

Advanced fatty liver conditions are frequently tied directly to metabolic dysfunction:

• Fatty liver disease affects more than half of all individuals living with Type 2 diabetes.
• The condition can transition into an active inflammatory stage that causes severe liver scarring, cirrhosis, or cancer.
• Many people with active liver damage still show completely normal liver enzymes on standard medical blood panels.
• Current guidelines recommend a baseline screening using the FIB-4 index, followed by a specialized FibroScan ultrasound if risk factors are high.

Treatment overlaps with broader diabetes care. Weight loss is the most effective intervention (5–10% reduces hepatic fat and inflammation; ≥10% can reverse fibrosis). GLP-1 receptor agonists and tirzepatide produce meaningful MASLD improvement, and pioglitazone improves MASH histology in selected patients. Resmetirom, FDA-approved in 2024 for MASH with significant fibrosis, is the first targeted therapy. Hepatology referral is appropriate when significant fibrosis is suspected.

Brain Health: Slowing Cognitive Decline and Mitigating Severe Hypoglycemia

Brain — cognitive decline. Diabetes roughly doubles the risk of dementia, including both vascular and Alzheimer-type. Mechanisms overlap with diabetes complications elsewhere: small-vessel injury in the brain, AGE accumulation, insulin signaling disruption, and recurrent hypoglycemia. Severe or recurrent hypoglycemia is independently associated with cognitive decline in older adults — one reason aggressive glucose targets are loosened in that population. Routine cognitive screening is not standard, but warning signs — repeated medication errors, missed appointments, difficulty managing the regimen, memory complaints — warrant evaluation, and regimen simplification often follows.

Mental Health: Actively Managing Clinical Depression and Diabetes Distress

Mental health — depression and diabetes distress. Depression substantially worsens complication outcomes, both biologically (cortisol, inflammation, autonomic effects) and behaviorally (adherence and follow-through with screening). It is one of the strongest predictors of medication non-adherence in chronic disease. Diabetes distress — the specific cognitive and emotional burden of constant self-management — is a related but distinct entity that also predicts worse outcomes. Both are treatable; both are developed in Article 9.

---

If You Already Have a Diagnosed Complication: Halting the Progression

Maybe a recent appointment revealed moderate retinopathy, or an ACR of 150, or loss of sensation in the feet. That is hard to hear.

What it means: you are past the earliest stage, but almost certainly not past the point where intervention helps.

The SGLT2 inhibitor kidney trials enrolled people who already had diabetic kidney disease — and still produced large reductions in progression.¹³,¹⁴ The blood pressure trials that prevent vision loss enrolled people who already had retinopathy.¹¹ FIDELIO-DKD, FIGARO-DKD, and FLOW enrolled people with established kidney disease, and all three produced benefit.¹⁸,²¹,²²

“I already have it” does not mean “it is too late.” It means now I know, and now I can act.

Staging changes management intensity, not just prognosis. A higher stage of retinopathy or kidney disease tightens screening intervals, brings in specialist involvement, and elevates the priority of organ-protective medications. The framework remains the same — catch progression early, intervene before the next stage. Useful questions for the visit: What stage am I, and what is the typical trajectory with treatment? How will we know if things are getting worse? What interventions have the best evidence at my stage? Are there organ-protective medications indicated for my situation that I am not on?

---

Warning Signs That Should Not Wait: Immediate Red Flags

Some symptoms warrant same-day evaluation rather than waiting for the next appointment.

Ophthalmic Emergencies: Wavy Lines, Vision Loss, and Floaters

Eyes. Straight lines look wavy — doorframes, window blinds, text on a page — that is macular edema until proven otherwise. A sudden shower of floaters or flashes like a camera going off in peripheral vision can signal vitreous hemorrhage or retinal detachment. A dark area creeping across vision from any direction is a retinal emergency. All warrant same-day ophthalmic evaluation.

Foot Emergencies: Can Diabetic Foot Charcot Be Reversed?

Feet. Any break in the skin — blister, cut, crack between toes — in a neuropathic foot warrants same-day evaluation. Spreading redness, red streaks, increasing warmth, or new drainage means infection may be spreading; intravenous antibiotics may be needed. A hot, swollen foot without a wound in someone with neuropathy is acute Charcot foot until proven otherwise. Fever plus any foot wound is an emergency department visit. Black discoloration is gangrene — a vascular surgery emergency.

Cardiac Emergencies: Managing Atypical Silent Ischemia Signs

Heart. Chest pressure, tightness, or pain; jaw, neck, or arm discomfort; sudden shortness of breath; cold sweats — these can be acute coronary syndrome. Call 911. Do not drive. Do not wait to see if it passes.¹⁹ Atypical presentations are more common in diabetes; if something feels wrong and cannot be explained, err on the side of getting checked.¹⁷

Cerebrovascular Emergencies: Immediate Stroke Sign Recognition

Stroke. Sudden weakness or numbness on one side of the face, arm, or leg; sudden difficulty speaking, understanding speech, or seeing; sudden severe headache or loss of balance. Call 911. Time-critical treatment exists but only within hours of onset.

Renal Monitoring: Understanding the Urine Albumin to Creatinine Ratio

Kidneys. New swelling in legs, ankles, or around the eyes can signal fluid retention from kidney or heart issues. Persistently foamy urine may suggest heavy protein loss, though this finding is non-specific. Blood pressure suddenly harder to control may reflect kidney disease progression. These are not emergencies but warrant prompt outpatient evaluation.

Metabolic Emergencies: Severe Hyperglycemia and Euglycemic DKA Risks

Severe hyperglycemia. Glucose that does not respond to usual correction, especially during illness, paired with persistent vomiting, deep rapid breathing, fruity breath, or fluctuating consciousness — these can signal diabetic ketoacidosis or hyperosmolar hyperglycemic state. Both are emergencies. People on SGLT2 inhibitors can develop DKA at near-normal glucose levels (euglycemic DKA); ketone testing is appropriate even when glucose is not high. Sick-day protocols are developed in Article 5; hypoglycemia receives dedicated coverage later in this series.

---

Tailoring Treatment for the Complications of Diabetes in Special Populations

Older Adults: Customizing Safe A1C Targets and Deprescribing

For older adults with multiple medical conditions, limited life expectancy, or high fall risk, treatment targets shift. A1C goals may be relaxed to <8% or even <8.5% when life expectancy is limited or hypoglycemia risk is significant — severe hypoglycemia in this group causes falls, fractures, cognitive impairment, and hospitalizations, and the microvascular benefits of tight control take years to manifest. Blood pressure targets may loosen (around 140/90) when orthostatic hypotension is a problem; standing blood pressure is checked. Sulfonylureas — particularly glyburide — are generally avoided; SGLT2 inhibitors need attention to volume status; metformin dose adjusts at lower eGFR.

Deprescribing — reviewing whether each medication is still providing benefit — becomes increasingly relevant. Statins are generally continued if tolerated; initiation after age 75 involves shared decision-making. Screening intensity is calibrated to whether findings would change management.

Pregnancy: Intensive Preconception Care and Retinal Check Cadences

Pregnancy with preexisting diabetes requires tightened glucose targets to prevent congenital anomalies (first trimester) and excessive fetal growth later. Typical targets: A1C <6.5% if achievable without significant hypoglycemia (or <7% if hypoglycemia risk is high); fasting <95 mg/dL; 1-hour postprandial <140; 2-hour postprandial <120.

Medications shift substantially. Insulin is the mainstay; pumps and continuous glucose monitoring are often expanded during pregnancy. Metformin may be continued in selected cases but is usually transitioned to insulin. SGLT2 inhibitors, GLP-1 receptor agonists, finerenone, and statins are discontinued. ACE inhibitors and ARBs are discontinued before conception when possible (fetal renal toxicity); methyldopa, labetalol, or nifedipine substitute for blood pressure control. For women with established cardiovascular disease, the decision to stop a statin before pregnancy is best discussed with the cardiology team — balancing potential fetal harm against maternal cardiovascular risk during the pregnancy itself.

Complication screening accelerates. Retinopathy can progress rapidly during pregnancy — screening is each trimester and continues for one year postpartum if retinopathy is present. Nephropathy can also accelerate; close monitoring of proteinuria and kidney function continues throughout. Preconception counseling, when possible, is the most effective intervention: optimizing A1C, transitioning medications, and confirming retinal status before conception reduces risk meaningfully more than addressing things in the first trimester.

A separate but related condition — gestational diabetes, diabetes first identified during pregnancy — has distinct management and follow-up. Women with prior gestational diabetes carry substantially elevated lifetime risk of Type 2 diabetes and warrant ongoing screening, typically every 1–3 years.

---

Sustaining Medication Adherence to Achieve Long-Term Organ Protection

The medications that prevent complications only work when taken consistently. Real-world adherence to chronic disease medications is often substantially lower than trial adherence — and the cardiovascular and kidney benefits in trials only apply when the medication is actually in the body.

Practical strategies that help: syncing all refills to the same day of the month (most pharmacies offer this); pairing medication with an existing routine rather than relying on memory; using a pill organizer to make missed doses visible. Understanding the purpose of each medication often matters more than any reminder system — knowing that an SGLT2 inhibitor is protecting kidneys, not just lowering glucose, sustains adherence when glucose feels fine.

If cost is a barrier, saying so directly is what unlocks options. Generics exist for most foundational medications. Patient assistance programs exist for many newer branded drugs. Clinicians and pharmacists cannot help with what they do not know. The most effective regimen is often the one a person can realistically sustain for years.

---

Putting It Together: The Complications of Diabetes Summary Matrix

System	Earliest detectable finding	What it signals	Key medications
Eyes	Microaneurysms on dilated exam	Retinal capillary injury	Glucose and blood pressure control; anti-VEGF / laser if proliferative or DME
Kidneys	Albuminuria (ACR 30–300), early eGFR decline	Filtration injury + systemic vascular risk	ACEi/ARB, SGLT2 inhibitor, finerenone, GLP-1 RA
Nerves	Loss of monofilament or vibration sense	Sensory protection failing	Glucose and BP control; duloxetine/pregabalin/gabapentin for pain; fall-prevention
Feet	LOPS, weak pulses, calluses at pressure points	Pre-ulcer state	Daily inspection, proper footwear, podiatry, vascular evaluation as needed
Peripheral arteries	Reduced pulses, abnormal ABI/TBI, claudication	Large-vessel atherosclerosis	Smoking cessation, statin, antiplatelet, supervised exercise, revascularization if severe
Heart and brain	Elevated BP, elevated LDL; albuminuria is also a CV marker	Atherosclerosis active throughout the system	Statin (± ezetimibe ± PCSK9i), BP control, SGLT2i/GLP-1 RA in T2D, smoking cessation; aspirin in secondary prevention
Liver	Elevated FIB-4 or elastography	MASLD / MASH	Weight loss, GLP-1 RA, tirzepatide, resmetirom for MASH with fibrosis
Cognitive	Subtle memory or executive-function changes; missed appointments or medication errors	Possible cognitive decline	Regimen simplification, avoid hypoglycemia, formal evaluation

Each row is a different disease process. They interact: intervention on a single driver (blood pressure, smoking, glucose) often moves multiple rows in the right direction.

---

Clinical Consultation Checklist: Questions to Ask at Every Visit

A short list that, if asked routinely, catches most missed opportunities:

• Are all my complication screenings up to date?
• What is my retinopathy stage, eGFR, ACR, and foot risk category?
• What are the trends in my kidney and cardiovascular numbers?
• Are there organ-protective medications I should be on that I am not?
• Are my vaccinations current?
• Can I get my screening schedule in writing?

---

Clinical Bottom Line: Asymptomatic Screening Shifts Trajectories

Diabetes complications develop in an asymptomatic phase over years. The retinopathy that causes blindness starts as microaneurysms visible only on screening. The kidney failure that requires dialysis starts as albumin in urine, detectable on a routine test. The amputation starts as a small wound on a numb foot.

Trials consistently show that early, comprehensive intervention — not just glucose control, but blood pressure, lipids, smoking cessation, and the modern organ-protective medications — changes outcomes by years. Steno-2’s 7.9-year survival gain came from systematically addressing everything and catching problems early. Each piece adds to the others; the benefits accumulate. And for those who already have a complication, intervention still meaningfully changes trajectory.

The concrete next step is to know the numbers — eGFR, ACR, retinopathy stage, foot risk category, A1C, blood pressure, LDL — get the screening schedule in writing, and ask whether the organ-protective medications indicated for the situation are on the regimen. That converts abstract knowledge into a system. Diabetes complications are not destinies. They are trajectories, and trajectories respond to attention paid before symptoms appear.

The screening system works because diabetes complications are detectable before they are irreversible.

---

What Comes Next: Navigating the Emotional and Behavioral Dimension

Article 9 examines the mental health dimension of diabetes — the emotional burden of constant self-management, the bidirectional connection between stress and glucose, and evidence-based approaches to depression and diabetes distress.

---

Key Terms: Essential Clinical Dictionary for Diabetes Care

ABI (ankle-brachial index): Ratio of ankle to arm blood pressure; values below 0.9 indicate peripheral artery disease, values above 1.4 indicate non-compressible calcified vessels (common in diabetes; toe-brachial index used instead).

ACR (albumin-to-creatinine ratio): Urine test for albumin leakage; a marker of kidney injury and systemic vascular risk.

AGEs (advanced glycation end products): Sugar-modified proteins formed slowly through Maillard chemistry; accumulate in long-lived tissue proteins and do not easily reverse.

Albuminuria: Albumin in urine above normal levels; reflects both kidney injury and systemic vascular risk.

Anti-VEGF injection: Intraocular injection of medication (bevacizumab, ranibizumab, aflibercept, faricimab) that blocks vessel-growth signaling; first-line for diabetic macular edema and increasingly for proliferative retinopathy.

CHA₂DS₂-VASc score: Risk score used to guide anticoagulation decisions in atrial fibrillation; diabetes contributes one point.

Charcot foot (Charcot neuroarthropathy): Inflammatory destruction of foot bones and joints in a neuropathic foot, often misdiagnosed as cellulitis or gout; requires prompt immobilization.

DME (diabetic macular edema): Fluid in the central retina causing central vision distortion.

eGFR (estimated glomerular filtration rate): Measure of kidney filtering capacity calculated from blood creatinine.

FIB-4: A non-invasive index calculated from age, AST, ALT, and platelet count; used to estimate liver fibrosis risk in MASLD.

HFpEF / HFrEF: Heart failure with preserved or reduced ejection fraction — two pumping-function subtypes; both more common in diabetes.

LOPS (loss of protective sensation): Inability to feel the 10-gram monofilament; the threshold beyond which small foot injuries can go unnoticed.

MASLD / MASH: Metabolic dysfunction-associated steatotic liver disease (formerly NAFLD) and its inflammatory subset MASH (formerly NASH); common in Type 2 diabetes.

Metabolic memory: The lasting biologic effect of sustained glucose control or lack of it, persisting even after current control changes.

Monofilament: A 10-gram nylon filament used to test foot sensation; inability to feel it indicates loss of protective sensation.

NPDR / PDR: Nonproliferative diabetic retinopathy (earlier stages) and proliferative diabetic retinopathy (advanced disease with abnormal new vessel formation).

PAD (peripheral artery disease): Atherosclerotic narrowing of arteries supplying the legs; in diabetes typically more distal, diffuse, and calcified than in non-diabetic populations.

Panretinal photocoagulation: Laser treatment that ablates peripheral retina to reduce growth-factor production and slow proliferative retinopathy.

Podocytes: Specialized kidney cells that maintain the filtration barrier; injured early in diabetic kidney disease.

Vitrectomy: Surgical removal of the vitreous gel; used for vitreous hemorrhage or tractional retinal detachment.

---

References

1. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83. https://doi.org/10.1186/s12933-018-0728-6
2. Nathan DM; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9–16. https://doi.org/10.2337/dc13-2112
3. Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59(11):2298–2307. https://doi.org/10.1007/s00125-016-4065-6
4. Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014;18(1):1–14. https://doi.org/10.4196/kjpp.2014.18.1.1
5. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–1070. https://doi.org/10.1161/CIRCRESAHA.110.223545
6. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98–107. https://doi.org/10.1038/nri2925
7. Tang WH, Martin KA, Hwa J. Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol. 2012;3:87. https://doi.org/10.3389/fphar.2012.00087
8. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA. 2010;304(6):649–656. https://doi.org/10.1001/jama.2010.1111
9. Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic Retinopathy Preferred Practice Pattern. Ophthalmology. 2020;127(1):P66–P145. https://doi.org/10.1016/j.ophtha.2019.09.025
10. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1):S1–S321. https://doi.org/10.2337/dc24-Sint
11. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–713. https://doi.org/10.1136/bmj.317.7160.703
12. Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2023. US Department of Health and Human Services; 2023. https://www.cdc.gov/kidneydisease/publications-resources/CKD-national-facts.html
13. Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. https://doi.org/10.1056/NEJMoa1811744
14. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. https://doi.org/10.1056/NEJMoa2024816
15. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. https://doi.org/10.2337/dc16-2042
16. Bus SA, Sacco ICN, Monteiro-Soares M, et al. Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2023 update). Diabetes Metab Res Rev. 2024;40(3):e3651. https://doi.org/10.1002/dmrr.3651
17. Valensi P, Lorgis L, Cottin Y. Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature. Arch Cardiovasc Dis. 2011;104(3):178–188. https://doi.org/10.1016/j.acvd.2010.11.013
18. Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229. https://doi.org/10.1056/NEJMoa2025845
19. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. J Am Coll Cardiol. 2021;78(22):e187–e285. https://doi.org/10.1016/j.jacc.2021.07.053
20. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. https://doi.org/10.1056/NEJMoa2107038
21. Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109–121. https://doi.org/10.1056/NEJMoa2403347
22. Pitt B, Filippatos G, Agarwal R, et al; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–2263. https://doi.org/10.1056/NEJMoa2110956
23. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol. 2021;78(12):1210–1222. https://doi.org/10.1016/j.jacc.2021.07.022
24. ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–1539. https://doi.org/10.1056/NEJMoa1804988
25. Nissen SE, Lincoff AM, Brennan D, et al; CLEAR Outcomes Investigators. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–1364. https://doi.org/10.1056/NEJMoa2215024